The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Sep. 24, 9:57 PM

Slide #22. Capricor Therapeutics, Inc. Secondary Offering

Company: Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Date announced: 9/15/2016
Shares Offered: 3,000,000
Date of Pricing: 9/16/2016
Price Per Share: $3.20
Secondary Offering Details: Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc., are acting as joint book-running managers for the offering. -updated 9/16- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced the pricing of its offerings of 3,000,000 shares of its common stock at an offering price of $3.20 per share, before underwriting discounts. 2,687,500 shares of Capricor's common stock will be purchased by the underwriters in an underwritten registered public offering and 312,500 shares will be purchased by Cedars-Sinai Medical Center, a stockholder of Capricor, from Capricor directly and not through the underwriters in a concurrent registered direct offering. Capricor has granted the underwriters a 30-day option to purchase up to an additional 403,125 shares of its common stock. The proceeds to Capricor from the offerings are expected to be approximately $8.7 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters' option. All shares of common stock to be sold in the offerings are being offered by Capricor. The offerings are expected to close on or about September 21, 2016, subject to customary closing conditions.

Capricor Therapeutics is a clinical-stage biotechnology company. Co.'s drug candidates include: CAP-1002, which consists of allogeneic cardiosphere-derived cells; Cenderitide (CD-NP), which belongs to a class of drugs called natriuretic peptides that provide a therapeutic option for the outpatient treatment of heart failure; Exosomes, which are nano-sized, membrane-enclosed vesicles, or bubbles, that are filled with select molecules, which, when released, send messages to neighboring cells to regulate cellular functions; CAP-1001, which consists of autologous CDCs; CU-NP, which is a pre-clinical rationally-designed natriuretic peptide; and CSps, which are multicellular clusters.
Open the CAPR Page at The Online Investor »

Company Name:  Capricor Therapeutics Inc
Website:  www.capricor.com
Sector:  Biotechnology
Number of ETFs Holding CAPR:  2
Total Market Value Held by ETFs:  $57236
Total Market Capitalization:  $64.00M
% of Market Cap. Held by ETFs:  0.09%
 

Open the CAPR Page at The Online Investor (in a new window) »

September 24, 2016    9:57 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
85th percentile
(ranked higher than approx. 85% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.